Focused on driving breakthrough innovation to save vision.

Learn More

Tavo Biotherapeutics is a biotech company developing novel treatments for glaucoma and retinal diseases.

By leveraging differentiated science and a deeply experienced team, we aim to develop transformative therapies that preserve vision by targeting the root biological mechanisms of disease.

Therapeutic Areas

Glaucoma

Retinal Disease

Tavo’s Approach

Disease Overview

Tavo is developing TAV-001, a potential disease-modifying topical therapy that takes a fundamentally different approach to glaucoma. Rather than treating pressure alone, TAV-001 is designed as an Autonomic Nervous System Modulator for Glaucoma (AMG) — a new class of therapy that works with the eye’s own regulatory systems to address the disease comprehensively at its source.

TAV-001 acts on the autonomic nervous system through three interconnected mechanisms:

Intraocular Pressure Reduction — TAV-001 modulates autonomic signaling to reduce the pressure caused by excess fluid production that ultimately damages the optic nerve.
Improved Ocular Perfusion — TAV-001 is a known vasodilator, which may increase blood flow and reduce ischemia at the optic nerve.
Neuroprotection — We believe TAV-001 dampens glutamate release and excitotoxicity that drive irreversible vision loss, attenuating the inflammatory cascade that damages retinal ganglion cells.

TAV-001 has completed a successful Phase 1b clinical trial in glaucoma patients and is currently being studied in a Phase 2 clinical trial.

Glaucoma

Retinal Disease

Tavo’s Approach

Disease Overview

Tavo is developing TAV-001, a potential disease-modifying topical therapy that takes a fundamentally different approach to glaucoma. Rather than treating pressure alone, TAV-001 is designed as an Autonomic Nervous System Modulator for Glaucoma (AMG) — a new class of therapy that works with the eye’s own regulatory systems to address the disease comprehensively at its source.

TAV-001 acts on the autonomic nervous system through three interconnected mechanisms:

Intraocular Pressure Reduction — TAV-001 modulates autonomic signaling to reduce the pressure caused by excess fluid production that ultimately damages the optic nerve.
Improved Ocular Perfusion — TAV-001 is a known vasodilator, which may increase blood flow and reduce ischemia at the optic nerve.
Neuroprotection — We believe TAV-001 dampens glutamate production and excitotoxicity that drive irreversible vision loss, attenuating the inflammatory cascade that damages retinal ganglion cells.

TAV-001 has completed a successful Phase 1b clinical trial in glaucoma patients and is currently being studied in a Phase 2 clinical trial.

Pipeline

Tavo’s pipeline spans two therapeutic areas in ophthalmology, with programs ranging from topical therapies for glaucoma to injectable biologics for retinal disease — each designed to modify the course of disease progression and vision loss.

Team

Tavo’s leadership team brings deep experience in ophthalmic drug development, clinical operations, and scaling biotech companies. Our Medical Advisory Board includes leading ophthalmologists and researchers from premier institutions.

Leadership

Board of Directors

Medical Advisory Board